CSV February 26, 2018 through February 26, 2020 See all Errata for USP–NF How to use
×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
  - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
  - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
  - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MEROPENEM FOR INJECTION	ASSAY/*Procedure*	*Second Supplement to USP42–NF37*	9216	31-Jan-2020	1-Feb-2020	*NA*	*NA*	In *Mobile phase*: Change *Solution A* to: *Buffer*
ALFADEX	CHEMICAL INFORMATION	*USP42–NF37*	5561	31-Jan-2020	1-Feb-2020	*NA*	*NA*	Change 972.84 to: 972.85
POLYETHYLENE GLYCOL	CHEMICAL INFORMATION	*USP42–NF37*	5882	31-Jan-2020	1-Feb-2020	*NA*	*NA*	See https://www.uspnf.com/sites/default/files/usp_pdf/EN/january-2020-errata-with-image.pdf for correction
<121> INSULIN ASSAYS	ASSAY/*Rabbit Blood Sugar Method—Quantitative*	*Revision Bulletin (Official May 01, 2019)*	Online	27-Dec-2019	1-Jan-2020	*NA*	*NA*	In *Standard stock solution*: Change of USP Insulin RS of the appropriate species to: of the USP Insulin Reference Standard of the appropriate species AND In *Sample stock solution*: Change of USP Insulin RS of the appropriate species. to: of the USP Insulin Reference Standard of the appropriate species.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
<857> ULTRAVIOLET-VISIBLE SPECTROSCOPY	QUALIFICATION OF UV-VIS SPECTROMETERS	*Second Supplement to USP42–NF37*	9570	27-Dec-2019	1-Jan-2020	*NA*	*NA*	In all instances in *Table 4*: Change to: ? AND In *Control of Photometric Response/Acidic Nicotinic Acid Solutions in 0.1 N Hydrochloric Acid*/paragraph 1: Change Using nicotinic acid solutions, the absorbance accuracy must be ± 0.01 $A_?$. to: Using nicotinic acid solutions, the absorbance accuracy must be ± 0.010 $A_?$ (for values below 1.00 $A_?$).
CUPRIC CHLORIDE	REAGENTS AND REFERENCE TABLES/ *Reagent Specifications*	*USP42–NF37*	6092	27-Dec-2019	1-Jan-2020	*NA*	*NA*	Change [7447-39-4]. to: [10125-13-0].
CYPROHEPTADINE HYDROCHLORIDE ORAL SOLUTION	IMPURITIES/*Organic Impurities*	*USP42–NF37*	1195	27-Dec-2019	1-Jan-2020	*NA*	*NA*	In *Standard solution*: Change in *Solution B* to: in *Diluent*
SODIUM BICARBONATE	IMPURITIES/*Carbonate/ Analysis*	*USP42–NF37*	Online	22-Nov-2019	1-Dec-2019	*NA*	*NA*	Remove the external reference to a reagent in Sodium Bicarbonate
ROPINIROLE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*Revision Bulletin (Official July 01, 2019)*	Online	22-Nov-2019	1-Dec-2019	*NA*	*NA*	In *Test 2* and *Test 3* in *Analysis*: Change Result$_1$ = C_1 × (1/L) × (M_{r1}/M_{r2}) × 100 to: Result$_1$ = C_1 × V × (1/L) × (M_{r1}/M_{r2}) × 100
<1430.5> ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA—SMALL ANGLE X-RAY SCATTERING AND SMALL ANGLE NEUTRON SCATTERING	6. EXPERIMENTAL CONSIDERATIONS	*Second Supplement to USP42–NF37*	Online	22-Nov-2019	1-Dec-2019	*NA*	*NA*	In *6.2 Resolution/6.2.1 Size resolution*: Change q_{min} < ?/d_{max} ?/d_{max} to: q_{min} < ?/d_{max}
<1430> ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA—GENERAL	1. OVERVIEW: GENERAL CHAPTERS BASED ON SCATTERING PHENOMENA	*Second Supplement to USP42–NF37*	9634	22-Nov-2019	1-Dec-2019	*NA*	*NA*	In Row 6 of Column 4 in *Table 1*: Change Also properties of condensated phrases to: Also properties of condensated phases
<1227> VALIDATION OF MICROBIAL RECOVERY FROM PHARMACOPEIAL ARTICLES	VALIDATION OF NEUTRALIZATION METHODS—RECOVERY COMPARISONS	*Second Supplement to USP42–NF37*	9616	22-Nov-2019	1-Dec-2019	*NA*	*NA*	In paragraph 1 in *Recovery on Agar Medium*: Change If it is necessary to solubilize the test stample, to: If it is necessary to solubilize the test sample,
25% TETRABUTYLAMMONIUM HYDROXIDE TS	REAGENTS AND REFERENCE TABLES/ *Solutions*	*Second Supplement to USP42–NF37*	9336	22-Nov-2019	1-Dec-2019	*NA*	*NA*	Change Transfer about 34.82 g to: Transfer about 77.1 g

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
0.1 N POTASSIUM HYDROXIDE VS	REAGENTS AND REFERENCE TABLES/ *Solutions*	*USP42–NF37*	6185	22-Nov-2019	1-Dec-2019	*NA*	*NA*	Change *Standardization*: Add 2 drops of phenolphthalein TS to 20 mL of 0.1 N potassium hydroxide VS. Titrate with 0.1 N hydrochloric acid VS until a permanent pale-pink color is produced. to: *Standardization*: Add 2 drops of phenolphthalein TS to 20 mL of 0.1 N hydrochloric acid VS. Titrate with the potassium hydroxide solution until a permanent pale-pink color is produced.
2,5-DIHYDROXYBENZOIC ACID	REAGENTS AND REFERENCE TABLES/ *Reagent Specifications*	*USP42–NF37*	6097	22-Nov-2019	1-Dec-2019	*NA*	*NA*	Change [303-07-1]. to: [490-79-9].
ZIPRASIDONE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Test 3/Tier 2*	*Revision Bulletin (Official October 01, 2019)*	Online	22-Nov-2019	1-Dec-2019	*NA*	*NA*	In *Buffer*: Change 6.8 g/L g to: 6.8 g/L AND In *Standard stock solution 2*: Change *Standard stock solution* to: *Standard stock solution 1* In *Standard solution*: Change USP Simvastatin RS in *Medium* to: USP Simvastatin RS in *Medium*. Transfer a portion of the solution to a centrifuge tube containing about 10 mg of *Prewashed manganese dioxide* per milliliter of transferred solution under test, and mix. Allow the mixture to stand for 30 min with occasional shaking, centrifuge, and use a portion of the clear supernatant.
SIMVASTATIN TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP42–NF37*	4009	22-Nov-2019	1-Dec-2019	*NA*	*NA*	
AMLODIPINE AND OLMESARTAN MEDOXOMIL TABLETS	IMPURITIES/*Organic Impurities*	*Second Supplement to USP42–NF37*	9101	22-Nov-2019	1-Dec-2019	*NA*	*NA*	In *Table 4*, *Footnote h*: Change 0.47, to: 0.45,
MEFENAMIC ACID CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*USP42–NF37*	2711	22-Nov-2019	1-Dec-2019	*NA*	*NA*	Change *Solution A*, *Mobile phase*, *Standard solution*, *Sample solution*, *Chromatographic system*, and *System suitability*: Proceed as directed in the *Assay*, making any necessary volumetric adjustments. to: *Solution A*, *Mobile phase*, *Standard solution*, *Chromatographic system*, and *System suitability*: Proceed as directed in the *Assay*, making any necessary volumetric adjustments. *Sample solution*: Take a portion of the solution under test, and dilute if necessary.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
<2022> MICROBIOLOGICAL PROCEDURES FOR ABSENCE OF SPECIFIED MICROORGANISMS—NUTRITIONAL AND DIETARY SUPPLEMENTS	BUFFER AND MEDIA/*Media*	*USP42–NF37*	8514	25-Oct-2019	1-Nov-2019	*NA*	*NA*	In Row 5 of Column 2 for L-Cystine in *Fluid Selenite–Cystine Medium*: Change 10.0 g to: 10.0 mg
<1229.2> STEAM STERILIZATION OF AQUEOUS LIQUIDS	BIOBURDEN/BIOLOGICAL INDICATOR METHOD/ *Routine Process Control*	*USP42–NF37*	8082	25-Oct-2019	1-Nov-2019	*NA*	*NA*	In the first paragraph: Change calibrartion to: calibration
<1228.4> DEPYROGENATION BY RINSING	ROUTINE PROCESS CONTROL	*USP42–NF37*	8067	25-Oct-2019	1-Nov-2019	*NA*	*NA*	In the first paragraph: Change WFI to: Water for Injection
<1222> TERMINALLY STERILIZED PHARMACEUTICAL PRODUCTS—PARAMETRIC RELEASE	INTRODUCTION	*USP42–NF37*	8021	25-Oct-2019	1-Nov-2019	*NA*	*NA*	In paragraphs 4 and 5: Change a probability of a PNSU to: a PNSU
<55> BIOLOGICAL INDICATORS—RESISTANCE PERFORMANCE TESTS	D-VALUE DETERMINATION	*USP42–NF37*	6385	25-Oct-2019	1-Nov-2019	*NA*	*NA*	In the third paragraph in *Procedure*: Change stated spore filter to: stated spore titer
HYPROMELLOSE ACETATE SUCCINATE	ASSAY	*USP42–NF37*	5772	25-Oct-2019	1-Nov-2019	*NA*	*NA*	In *Content of Methoxy and 2-Hydroxypropoxy Groups/Analysis*: Change Result = $(r_{UM}/r_{SM}) \times (C_S/C_U) \times (M_{r1}/M_{r2})$ to: Result = $(r_{UM}/r_{SM}) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$ AND Change Result = $(r_{UI}/r_{SI}) \times (C_S/C_U) \times (M_{r1}/M_{r2})$ to: Result = $(r_{UI}/r_{SI}) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$
GADOTERIDOL	*Limit of gadoteridol related compound A*	*USP42–NF37*	2020	25-Oct-2019	1-Nov-2019	*NA*	*NA*	In *Chromatographic system*: Change packing L21 to: packing L47
PAROXETINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP42–NF37*	8788	27-Sep-2019	1-Oct-2019	*NA*	*NA*	In USP Paroxetine Related Compound G RS: Change 405.46 to: 441.92

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PENICILLAMINE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*Revision Bulletin (Official June 11, 2019)*	Online	27-Sep-2019	1-Oct-2019	*NA*	*NA*	In *Procedure for a pooled sample*/*Analysis*: Change Result = $(A_U/A_S) \times (C_S/C_U) \times V \times (1/L) \times 100$ to: Result = $(A_U/A_S) \times C_S \times V \times (1/L) \times 100$ AND Change C_S = concentration of USP Penicillamine RS in the *Standard solution* (µg/mL) to: C_S = concentration of USP Penicillamine RS in the *Standard solution* (mg/mL) AND Delete C_U = nominal concentration of penicillamine in the *Sample solution* (µg/mL) AND In *Procedure for a unit sample*/*Analysis*: Change Result = $(r_U/r_S) \times (C_S/C_U) \times V \times (1/L) \times 100$ to: Result = $(r_U/r_S) \times C_S \times V \times (1/L) \times 100$ AND Delete C_U = nominal concentration of in the *Sample solution* (mg/mL) In *Chromatographic system*: Delete *Detector temperature*: 25°
BENZALDEHYDE	ASSAY/*Procedure*	*USP42–NF37*	5586	27-Sep-2019	1-Oct-2019	*NA*	*NA*	In the first equation in *Analysis*: Change C_S = concentration of USP Withanoside IV RS in *Standard solution A* (mg/mL) to: C_S = concentration of USP Withanolide A RS in *Standard solution A* (mg/mL)
ASHWAGANDHA ROOT DRY EXTRACT	COMPOSITION/*Content of Withanolides*	*USP42–NF37*	4724	27-Sep-2019	1-Oct-2019	*NA*	*NA*	Change Zinc sulfate (1:1) monohydrate 179.46 to: Zinc sulfate (1:1) monohydrate 179.45 [7446-19-7]. AND Change 287.56 to: 287.54
ZINC SULFATE	CHEMICAL INFORMATION	*USP42–NF37*	4649	27-Sep-2019	1-Oct-2019	*NA*	*NA*	Change $2(407.51/480.43)C(r_U/r_S)$ to: $2000(407.51/480.43)C(r_U/r_S)$
TRIFLUOPERAZINE HYDROCHLORIDE TABLETS	*Assay*	*USP42–NF37*	4473	27-Sep-2019	1-Oct-2019	*NA*	*NA*	

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCHLOROTHIAZIDE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*USP42–NF37*	2171	27-Sep-2019	1-Oct-2019	*NA*	*NA*	In *Empty capsules solution*: Change Place 10 Capsules to: Place 10 empty capsules
DESFLURANE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	1230	27-Sep-2019	1-Oct-2019	*NA*	*NA*	In USP Desflurane Related Compound A RS: Change Bis-(1,2,2,2-tetrafluoroethyl)ether. to: Bis-(1,2,2,2-tetrafluoroethyl)ether; Also known as: 1,1,1,2-Tetrafluoro-2-(1,2,2,2-tetrafluoroethoxy)ethane.
DESFLURANE	CHEMICAL INFORMATION	*USP42–NF37*	1230	27-Sep-2019	1-Oct-2019	*NA*	*NA*	Change (±)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether to: (±)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether; 2-(Difluoromethoxy)-1,1,1,2-tetrafluoroethane.
BENDAMUSTINE HYDROCHLORIDE FOR INJECTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	487	27-Sep-2019	1-Oct-2019	*NA*	*NA*	In USP Bendamustine Related Compound B RS: Change 4-(1-Methyl-5-morpholino-1*H*-benzimidazol-2-yl)butanoic acid. $C_{16}H_{21}N_3O_3$ 303.36 to: 4-(1-Methyl-5-morpholino-1*H*-benzimidazol-2-yl)butanoic acid hydrochloride. $C_{16}H_{21}N_3O_3 \cdot x$HCl

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
BENDAMUSTINE HYDROCHLORIDE FOR INJECTION	IMPURITIES/*Organic Impurities USP42–NF37*		487	27-Sep-2019	1-Oct-2019	*NA*	*NA*	In *Table 2*: Change Bendamustine related compound B to: Bendamustine related compound B[a] AND Change Bendamustine related compound C[a] to: Bendamustine related compound C[b] AND Change Bendamustine related compound G[a] to: Bendamustine related compound G[b] AND Change Bendamustine related compound I[a] to: Bendamustine related compound I[b] AND Change [a] This process impurity is controlled in the drug substance monograph. It is included in the table for identification only, and it is not to be reported in the total impurities. to: [a] It is a free base of USP Bendamustine Related Compound B RS: 4-(1-Methyl-5-morpholino-1*H*-benzimidazol-2-yl)butanoic acid. [b] This process impurity is controlled in the drug substance monograph. It is included in the table for identification only, and it is not to be reported in the total impurities.
ANAGRELIDE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Analysis*	*USP42–NF37*	329	27-Sep-2019	1-Oct-2019	*NA*	*NA*	Change Result = (r_U/r_S) x (C_S/C_U) x (M_{r1}/M_{r2}) x (V/L) x 100 to: Result = (r_U/r_S) x C_S x (M_{r1}/M_{r2}) x (V/L) x 100 AND Delete C_U = nominal concentration of anagrelide in the *Sample solution* (mg/mL)
AMIODARONE HYDROCHLORIDE	CHEMICAL INFORMATION	*USP42–NF37*	253	27-Sep-2019	1-Oct-2019	*NA*	*NA*	See https://www.uspnf.com/sites/default/files/usp_pdf/EN/september-2019-errata-with-image.pdf for correction.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MORPHINE SULFATE EXTENDED-RELEASE CAPSULES	IMPURITIES/*Organic Impurities*	*USP42–NF37*	Online	30-Aug-2019	1-Sep-2019	*NA*	*NA*	Change *Diluent*, *Solution A*, *System suitability solution*, *Chromatographic system*, and *Sample solution*: Proceed as directed in the *Assay*. to: *Diluent*, *Buffer solution*, *Solution A*, *Solution B*, *Mobile phase*, *System suitability solution*, *Chromatographic system*, and *Sample solution*: Proceed as directed in the *Assay*.
OLMESARTAN MEDOXOMIL TABLETS	IMPURITIES/*Organic Impurities*	*Revision Bulletin (Official March 19, 2019)*	Online	30-Aug-2019	1-Sep-2019	*NA*	*NA*	In the *Analysis*: Change C_S = concentration of in the *Standard solution* (mg/mL) to: C_S = concentration of USP Olmesartan Medoxomil RS in the *Standard solution* (mg/mL)
<1160> PHARMACEUTICAL CALCULATIONS IN PHARMACY PRACTICE	19. MEAN KINETIC TEMPERATURE	*USP42–NF37*	7831	30-Aug-2019	1-Sep-2019	*NA*	*NA*	In *19.4 Example Calculations of MKT for CRT Storage Evaluation/ Example 3—Calculation of Annual MKTStep 3*: Change 3.354 to: 3.340 AND In *Step 4*: Change 2.795 to: 2.783 AND In *Step 5*: Change ?33.511 to: ?33.515 AND In *Step 6*: Change 298.410 to: 298.372
SILDENAFIL CITRATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	4002	30-Aug-2019	1-Sep-2019	*NA*	*NA*	In USP Sildenafil Related Compound A RS: Change 5-[2-Ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]-1-methyl-3-(2-methylpropyl)-1,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one. $C_{23}H_{32}N_6O_4S$ 488.60 to: 5-[2-Ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl]-1-methyl-3-(2-methylpropyl)-1,6-dihydro-7*H*-pyrazolo[4,3-*d*]pyrimidin-7-one; Also known as 1-{[3-(6,7-Dihydro-1-methyl-7-oxo-3-isobutyl-1*H*-pyrazolo[4,3-*d*]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl}-4-methylpiperazine. $C_{23}H_{32}N_6O_4S$ 488.61

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LEVOFLOXACIN	CHEMICAL INFORMATION	*USP42–NF37*	2552	30-Aug-2019	1-Sep-2019	*NA*	*NA*	Change Anhydrous [100986-85-41]. to: Anhydrous [100986-85-4].
MECLOFENAMATE SODIUM	CHEMICAL INFORMATION	*USP42–NF37*	2706	30-Aug-2019	1-Sep-2019	*NA*	*NA*	Change 336.15 to: 336.14 AND Change [6385-02-0]; to: [67254-91-5]; AND Change UNII: 9MMQ0YER4E. to: UNII: 94NJ818U2W.
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Revision Bulletin (Official August 01, 2018)*	Online	30-Aug-2019	1-Sep-2019	*NA*	*NA*	In USP Fexofenadine Related Compound A RS: Change Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl. to: 2-(4-{4-[4-(Hydroxydiphenylmethyl)piperidin-1-yl]butanoyl}phenyl)-2-methylpropanoic acid; Also known as Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl.
FEXOFENADINE HYDROCHLORIDE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Revision Bulletin (Official November 01, 2018)*	Online	30-Aug-2019	1-Sep-2019	*NA*	*NA*	In USP Fexofenadine Related Compound A RS: Change Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl. to: 2-(4-{4-[4-(Hydroxydiphenylmethyl)piperidin-1-yl]butanoyl}phenyl)-2-methylpropanoic acid; Also known as Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl.
FEXOFENADINE HYDROCHLORIDE CAPSULES	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	1830	30-Aug-2019	1-Sep-2019	*NA*	*NA*	In USP Fexofenadine Related Compound A RS: Change Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl. $C_{32}H_{37}NO_4$ 538.12 to: 2-(4-{4-[4-(Hydroxydiphenylmethyl)piperidin-1-yl]butanoyl}phenyl)-2-methylpropanoic acid; Also known as Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl. $C_{32}H_{37}NO_4$ 499.65

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FEXOFENADINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	1828	30-Aug-2019	1-Sep-2019	*NA*	*NA*	In USP Fexofenadine Related Compound A RS: Change Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl. to: 2-(4-{4-[4-(Hydroxydiphenylmethyl)piperidin-1-yl]butanoyl}phenyl)-2-methylpropanoic acid; Also known as Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-?,?-dimethyl.
CIDOFOVIR INJECTION	IMPURITIES/*Organic Impurities*	*USP42–NF37*	981	30-Aug-2019	1-Sep-2019	*NA*	*NA*	In *Table 1*: Change 0.56 to: 0.59

Pagination

- Current page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Next page Next ›
- Last page Last »